Clinical Study

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In Pd L1?Selected Patients With Completely Resected S

Posted Date: May 14, 2017

  • Investigator: Nagla Abdel Karim
  • Co-Investigator: Kimberly Jacob Anderson
  • Specialties: Hematology/Oncology, Oncology, Cancer, Lung Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is a

Criteria:

To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer

Keywords:

Go29527, Cancer, Resected Nsclc, Lung, Null

For More Information:

Uc Cancer Institute
5135847698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.